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OBJECTIVE: To evaluate serum C-peptide in 88 patients from a multiethnic population with Type-1 diabetes and
variable disease durations.
METHOD: Eighty-eight patients with a mean disease duration of 8.1¡7.6 years were included and underwent
C-peptide measurement before and after glucagon stimulation. Chi-squared and Mann Whitney U-tests were
used to compare the variables between groups (all two-tailed, a =0.05). Spearmans correlation coefficient was
used to test the association between the continuous variables. Logistic regression was used for the multivariate
analysis. Twenty-eight (31.8%) individuals had significantly detectable C-peptide levels after stimuli,
particularly those with a shorter disease duration (p,0.001).
RESULTS: Patients with detectable C-peptide levels required lower insulin doses (p,0.009) and had similar
HbA1C results (p=0.182) and fewer chronic complications (p=0.029).
CONCLUSION: C-peptide detection was common in Type-1 diabetics, particularly shortly after being diagnosed.
This result may have clinical implications.
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& INTRODUCTION
Type-1 diabetes mellitus is characterized by destroyed
pancreatic b cells, insulin deficiency and hyperglycemia
(1,2). The progression of this process is heterogeneous and
may range from months to many years (3,4). For long
periods after being diagnosed, some Type-1 diabetes
patients maintain a residual b-cell function (5), which may
be associated with reducing the risk of complications and
hypoglycemia and improving metabolic control (6-10). C-
peptide is considered a reliable method for estimating the b-
cell residual function (5-7), particularly after glucagon
stimulation or a mixed meal. Most studies that have
evaluated the C-peptide secretion in Type-1 diabetes have
included Caucasians or Asians. Little is known about
insulin secretion in individuals of other ethnicities with
Type-1 diabetes. The aim of this study was to evaluate the b-
cell function in multiethnic Type-1 diabetes patients with
variable disease durations using C-peptide measurements
after glucagon stimulation.
& RESEARCH DESIGN AND METHODS
Volunteers who had Type-1 diabetes (11) with short
(Group 1) and long (Group 2) disease durations (#5 years
and .5 years, respectively) were included in this cross-
sectional study. A diabetes diagnosis was based on the
American Diabetes Association criteria (11). The patients’
clinical and epidemiological data were obtained from
questionnaires and medical records, and all participants
provided informed written consent. Blood samples from
each patient were measured for fasting glucose and
stimulated C-peptide (6 minutes after intravenous injections
of 1 mg of glucagon), glycosylated hemoglobin (HbA1C)
and anti-glutamic acid decarboxylase antibody (GADA).
The tests were performed if a patient’s fasting capillary
glucose measured between 70 and 200 mg/dL. The
participants were classified as whites and non-whites based
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on their phenotypes and family backgrounds. C-peptide
was determined using chemiluminescence (Immulite DPC;
UK). A C-peptide level $0.5 ng/dL was considered
detectable (reference 1.1 to 5.0 ng/mL). The inter- and
intra-assay coefficients of variation (CV) were 7.6% and
8.2%, respectively. GADA was determined using radio-
immunoassay (RSR-Limited, Cardiff, UK). Values .1.0 U/
mL were considered positive. The inter- and intra-assay CVs
were 4.9 to 7.0% and 3.6 to 3.7%, respectively. The statistical
analyses were performed using SAS 6.1 version (SAS
Institute Inc., Cary, NC). Chi-squared and Mann Whitney
U-tests were used to compare the variables between the
groups (all two-tailed, a= 0.05). Spearmans correlation
coefficient was used to test the association between the
continuous variables. Logistic regression was used for the
multivariate analysis.
& RESULTS
The study population comprised 88 individuals with
Type-1 diabetes. The characteristics of the study group are
shown in Table 1. Fasting C-peptide was detectable in 19
patients (21.6%), and these C-peptide levels were within the
normal range in 7 (8%) patients. After the glucagon
stimulus, C-peptide was detectable in 31.8% of the patients
(n = 28, p= 0.004) and within the normal range in 14.8% of
the patients (n = 13, p= 0.016). The mean C-peptide titers in
the patients with detectable C-peptide levels were 1.3¡0.8
ng/ml (fasting) and 1.6¡1.2 ng/ml (after the stimulus).
Given the superiority of C-peptide (after the stimulus) over
the fasting measurement, the former was used for the
following tests. Adverse events occurred in 35.2% of the
patients (n = 30) after the glucagon infusion (e.g., transient
mild nausea that was reversible within minutes in most
cases, vomiting, paresthesia and malaise).
There was an association between the detectable C-
peptide levels and the diabetes disease duration (detectable
CP = 5¡7.5 vs. undetectable CP = 10¡6.99 years, p,0.001),
but there was no correlation between the C-peptide titers
and the Type-1 diabetes duration (r = -0.342, p= 0.08). In
group 1, the patients with detectable C-peptide levels had a
shorter Type-1 diabetes duration (2.01¡1.4 vs. 3.04¡1.5
years, p= 0.034). The patient’s age at disease onset, ethnicity,
gender, DKA at diagnosis and GADA status were not
associated with the C-peptide detection. GADA was
positive in 43.7% of patients. Patients with detectable C-
peptide levels had a lower mean age than the other patients
(p= 0.001), but this link disappeared after the multivariate
analysis. There was a correlation between overweight
(BMI$25 kg/m2) and undetectable C-peptide levels
(p= 0.06).
Fasting glucose was not associated with C-peptide
detection (p= 0.16). The patients with detectable C-peptide
levels required lower insulin doses/kg than the other
patients (0.61¡0.34 vs. 0.85¡0.28, p,0.009), but had similar
HbA1c levels (8.49¡1.9 vs. 9.5¡2.6, p= 0.182). These results
were observed in the sample as a whole and separately in
each group. C-peptide detection was also linked to a lower
frequency of chronic complications (3.7% vs. 21.7%,
p= 0.029) but not to retinopathy or nephropathy individu-
ally. In group 2, other autoimmune diseases (usually
thyroid diseases) occurred more frequently in the patients
with detectable C-peptide levels (p= 0.018). This association
was not observed in group 1 (p= 0.53). After the logistic
regression analysis, the link between the detectable C-
peptide levels and the lower insulin doses (in use and with
the Type-1 diabetes duration) remained significant.
& DISCUSSION
This study evaluated the frequency and clinical implica-
tions of C-peptide detection in Type-1 diabetes patients.
This study population is particularly interesting because of
the complex and mixed ethnic backgrounds of the patients.
Most studies that have evaluated pancreatic function in
Type-1 diabetes were performed in Caucasian and Asian
patients. This study provides a unique opportunity to
improve our knowledge of the progression of b-cell
Table 1 - Clinical characteristics of patients grouped by disease durations.
Disease duration
Group 1 (#5 years) Group 2 (.5 years) Total p-value
Sex Female n (%) 14(35.9) 34(68.8) 48(54.0) 0.002
Male n (%) 25(64.1) 15(31.2) 40(46.0)
Ethnicity White n (%) 19(48.7) 32(64.6) 51(57.5) 0.13
Non-white n (%) 20(51.3) 17(35.4) 37(42.5)
Mean actual age (years) 18.6¡5.6 26.9¡9.1 23.1¡8.8 ,0.001
Mean diagnostic age (years) 16.5¡5.7 13.3¡7.9 14.7¡7.2 0.004
Mean disease duration (years) 2.51¡1.51 13.73¡6.72 8.7¡ 7.6 ,0.001
DKA at diagnosis n (%) Yes 8(20.5) 21(41.7) 29(33.0) 0.022
No 31(79.5) 27(56.3) 59(67.8)
Mean BMI (kg/m2 ¡SD) 21.1¡3.5 23.6¡3.2 22.4¡3.5 ,0.001
HbA1C (mean ¡SD) 8.97¡2.29 8.45¡1.62 8.6¡1.95 0.22
Mean insulin dose/kg 0.72¡0.34 0.87¡0.29 0.8¡0.3 0.023
Detectable CP n (%) Fasting (CP1) 16(41) 3(6.1) 19(21.6) ,0.001
Stimulated (CP2) 23(63.9) 5(10.2) 28(31.8) ,0.001
Preserved CP n (%) Fasting (CP1) 6(15.4) 1(2.0) 7(8) 0.029
Stimulated (CP2) 11(28.2) 2(4.1) 13(14.8) 0.009
Other Auto-immune diseases n (%)* 6 (15) 7(14.5) 13(14.7) 0.95
GADA 24(62.5) 14(29.8) 38(43.7) 0.004
Total number of patients 39 49 88
BMI – Body mass index, HBA1c – Glycohemoglobin, DKA- Diabetic ketoacidosis, CP – C-peptide. * Thyroid disease in 12 cases, Sjogren’s syndrome and
rheumatoid arthritis in one case each.
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secretion in patients with Type-1 diabetes in our population
because it is still unclear whether the results that were
obtained in previous studies can be extrapolated to other
ethnic populations, such as ours.
The tests were performed after the patients were
stimulated with glucagon, which is a faster method for
increasing b-cell secretion compared with the mixed meal
test. However, nausea and flushing may occur more
frequently as adverse events (5-7,12). This study found that
adverse events occurred in 35.2% of patients. These adverse
events included mild and transient nausea (in most cases),
which suggested that C-peptide measurement after gluca-
gon infusion can be well tolerated. At the beginning of this
study, both tests were considered equivalent in the
literature (7), and the mixed meal test was preferable (13).
We have shown that a significant proportion of patients
with Type-1 diabetes had detectable C-peptide levels, and
these levels were higher than those observed in the Diabetes
Control and Complications Trial Research Group DCCT
(8,10). We also compared the serum C-peptide levels
between individuals with short and long disease durations
(#5 and .5 years, respectively) of Type-1 diabetes. As
expected, detectable C-peptide levels occurred more fre-
quently in the individuals with shorter disease durations,
which indicated that the progression of the b cell destruc-
tion occurred primarily during the first years of the disease
(8,13-16). However, a significant proportion of the patients
with long-standing Type-1 diabetes had detectable levels of
C-peptide. This finding was compatible with the anatomo-
pathological data that described the presence of insulin cells
in Type-1 diabetes patients with long disease durations (5).
In a group of patients with extremely favorable clinical
outcomes and fewer diabetic complications, Keenan et al.
have reported a surprisingly large number (18%) of Type-1
diabetes patients with disease durations .50 years and
detectable C-peptide levels (17). Recently, using an ultra-
sensitive assay, Wang et al. have reported residual C-
peptide levels in patients with long-standing Type-1
diabetes (18). However, the potential clinical implications
of sustained b-cell function have been reported only for
those patients with C-peptide levels above the approximate
threshold that was used in our study (8).
One could question whether the patients with Type-1
diabetes and detectable C-peptide levels actually have
Type-1 diabetes rather than other forms of diabetes.
However, most patients needed insulin shortly after their
diagnoses, were not overweight and lacked a significant
family history of diabetes in more than one generation; these
histories make other diagnoses, such as Type-2 diabetes and
Maturity Onset Diabetes of the Young (MODY), unlikely.
However, we cannot exclude the possibility that atypical
forms of diabetes could be present in populations with
mixed ethnic backgrounds, particularly those with GADA (-
). Although the GADA prevalence was low in this study
group (19), it is likely that its positivity has decreased over
the years (20,21).
We found an association between autoimmune comorbid-
ities and detectable C-peptide levels after stimulating
patients with long disease durations, particularly in patients
with thyroid diseases. Although the sample size was
limited, this association has not been reported in other
studies (22). Vondra et al. reported the exact opposite
association, with a lower frequency of autoimmune
comorbidities in patients with Type-1 diabetes and detect-
able C-peptide levels (23).
It is known that short- and long-term glycemic control
may influence b-cell function in patients with Type-1
diabetes. However, previous data have indicated that
residual pancreatic function may influence glycemic control
(8,24,25). In this study, we excluded patients with glycemia
,70 or .200 mg/dl to minimize any possible interference.
Although the patients with Type-1 diabetes and detectable
C-peptide levels had similar glycemic control, these patients
used lower daily insulin doses, which indicated that
maintaining endogenous insulin secretion might reduce
the insulin requirements of patients with Type-1 diabetes.
The association between chronic complications and
residual C-peptide levels was also analyzed (25,26). We
found a link between C-peptide and chronic complications
as a whole but not with retinopathy or nephropathy
separately. It is possible that the sample size and the small
number of individuals with chronic complications included
in this study might have influenced our results.
To summarize, this study identified a significant number
of individuals with Type-1 diabetes (of both short and long
duration) with detectable C-peptide levels. It is possible that
this residual b cell secretion is associated with a lower
insulin requirement, a lower frequency of chronic complica-
tions and a higher frequency of other autoimmune diseases.
However, prospective studies are still needed to resolve
these questions.
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